MAP2K1: A Potential Drug Target for Pain and Fibrosis (G5604)

Target Name: MAP2K1

NCBI ID: G5604

MAP2K1

MAP2K1: A Potential Drug Target for Pain and Fibrosis

MAP2K1, also known as MAPKK1, is a protein that is expressed in various tissues throughout the body. It is a member of the MAPKK family, which includes several related proteins that play a crucial role in cellular signaling pathways. One of the most well-known MAPKKs is p38, which is a key mediator of inflammation, stress, and cell survival. MAP2K1, on the other hand, is different from p38 in several ways, including its structure, function, and potential as a drug target.

MAP2K1 is a 21-kDa protein that is expressed in a variety of tissues, including neurons, muscle cells, and blood vessels. It is highly conserved, with a calculated pI of 6.9 and a predicted localization in the cytoplasm. MAP2K1 is a protein that can interact with several different protein partners, including casein kinase (CK) 3, which is a critical regulator of the MAPK signaling pathway.

MAP2K1 functions as a negative regulator of the MAPK signaling pathway. It can inhibit the activity of casein kinase 3, which in turn can prevent the phosphorylation of several target proteins. This means that when casein kinase 3 is activated, it can cause MAP2K1 to become phosphorylated, which in turn can inhibit its activity. This is the opposite of what would be expected, as casein kinase 3 is typically activated in response to MAPK signaling.

MAP2K1 is a drug target that has been identified as a potential therapeutic agent for several diseases. One of the main reasons for its potential as a drug is its role in the regulation of pain. MAP2K1 has been shown to play a role in the development and progression of pain conditions, including neuropathic pain and chronic pain. Additionally, MAP2K1 has also been shown to be involved in the regulation of inflammation and fibrosis, which are two other potential causes of pain.

Another potential mechanism by which MAP2K1 may contribute to pain is its role in the regulation of pain perception. MAP2K1 has been shown to interact with the neurotransmitter GABA, which is involved in the regulation of pain perception. Additionally, MAP2K1 has also been shown to interact with the neurotransmitter glutamate, which is involved in pain modulation.

MAP2K1 has also been shown to be involved in the regulation of cell survival and proliferation. It has been shown to play a role in the regulation of cell cycle progression, as well as the regulation of apoptosis. Additionally, MAP2K1 has also been shown to interact with the protein p53, which is involved in the regulation of apoptosis.

MAP2K1 has also been shown to be involved in the regulation of inflammation and fibrosis. It has been shown to play a role in the regulation of inflammation, as well as the regulation of fibrosis. Additionally, MAP2K1 has also been shown to interact with the protein TGF-β, which is involved in the regulation of fibrosis.

In conclusion, MAP2K1 is a protein that has been shown to play a role in several important cellular processes, including the regulation of pain, inflammation, and fibrosis. Its unique function as a negative regulator of the MAPK signaling pathway makes it a potential therapeutic agent for a variety of diseases. Further research is needed to fully understand the role of MAP2K1 in cellular signaling pathways and its potential as a drug.

Protein Name: Mitogen-activated Protein Kinase Kinase 1

Functions: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis

The "MAP2K1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP2K1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets